LKA651

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Diabetic Macular EdemaMacular EdemaNeovascular Age-related Macular DegenerationRetinal Vein Occlusions

Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

CompletedNCT02867735

Novartis PharmaceuticalsDiabetic Macular Edema, Macular Edema, Neovascular Age-related Macular Degeneration +1

Start: 2016-09-21End: 2018-02-15Updated: 2022-04-15

Phase 2

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

CompletedNCT03927690

Novartis PharmaceuticalsDiabetic Macular Edema

Start: 2019-05-24End: 2022-08-31Updated: 2024-06-20